louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06366737: En-mass Retraction by KILBON Versus CAT Appliances
Official title: Effectiveness Of Lingual Retractor Versus Clear Aligner Appliances In En-mass Retraction Of Maxillary Anterior Teeth Segment In Adult Patients: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Maxillary Prognathism
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-04-16
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: en-mass retraction by lingual retractor versus clear alighner therapy

Detailed description: Comparative Effectiveness Of Lingual Retractor Versus Clear Aligner Appliances In Adult Patients With Maxillary Dentoalveolar Protrusion Treated By Upper First Premolars Extraction And Enmass Retraction Of Maxillary Anterior Teeth Segment Using Palatal Orthodontic Miniscrews :A Randomized Clinical Trial

Eligibility criteria: Inclusion Criteria:

* adult patients with maxillary dentoalveolar protrusion with mild crowding

Exclusion Criteria:

* - adult patients with maxillary dentoalveolar protrusion with moderate to severe crowding

Primary outcomes:
measure: Patient satisfaction during & after phase I treatment.
timeFrame: 6 months
Secondary outcomes:
measure: inclination of upper anterior teeth
timeFrame: 6 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry
Study officials:
References:
Clinical trial NCT01134237: Intrapleural Urokinase for Retained Hemothorax
Official title: Intrapleural Thrombolytic Treatment With Urokinase for Retained Hemothorax: A Prospective Double-blinded Randomized Multicenter Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Retained Hemothorax
Keywords: non-surgical rate
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2010-05-31
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Intrapleural thrombolytic treatment with urokinase for retained hemothorax is effective and safe. However, previous study was limited in prospective observation study without control group.

Detailed description: We will recruit 32 patients in this study. The patients with retained hemothorax will be randomly divided into the urokinase group and the placebo group. In the urokinase group, urokinase 100,000 IU in 100 mL NaCl will be injected into the intrapleural space. We will record the daily drainage amount and evaluate the therapeutic effect by the chest X-ray. The therapeutic effect, safety, hospital stay, and medical cost between the two groups will be compared. This study will be done in four medical centers in northern Taiwan.

Eligibility criteria: Inclusion Criteria:

1. Retained hemothorax: it is defined as chest X-ray revealing obvious blood clot in pleural cavity after tube thoracostomy drainage for 3 days. The chest tubes are in good location and have no obstruction. The physician thinks the blood clot is difficult to drain.
2. Age: full 18 year-old

Exclusion Criteria:

1. Pregnancy
2. Active bleeding
3. Coagulopathy, e.g. congenital or acquired coagulation abnormality, platelet count less than 100,000 /μL, international normalized ratio (INR) more than 1.5, or partial thromboplastin time, PTT, more than 50 seconds after treatment.
4. Cerebrovascular accident within 30 days
5. History of intracranial tumor or vascular abnormality
6. Have received thoracic surgery
7. Have received pleurodesis
8. Wish to receive thoracoscopic surgery for hematoma evacuation directly
9. Allergy to urokinase
10. Sepsis
11. Shock
12. People who are less than 18 years of age, prisoners, aborigines.

Primary outcomes:
measure: non-surgical rate
timeFrame: about 5 days
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Chin-Chih Chang
Study officials:
affiliation: National Taiwan University Hospital
name: Chin-Chih Chang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06033937: COMPETE Cohort Study
Official title: Comparison of the Effect of Device Closure in Alleviating Migraine With Patent Foramen Oval: COMPETE Cohort Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: PFO - Patent Foramen Ovale
Migraine
Lead sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Sponsor class: OTHER
First posted: 2023-09-13
Enrollment: 242
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with PFO and migraine who met the eligibility criteria are recruited for this study.

Brief summary: Migraine attacks are episodic disorder that affects approximately 12% of the population, and studies have shown that 41-48% of migraineurs have a combination of patent foramen ovale (PFO). Clinical Observational studies have been linking PFO occlusion with the effectiveness in improving migraine symptoms and reducing the frequency of attacks. However, several RCTs have shown negative primary results, making it unclear whether PFO occlusion is effective in treating migraine. Our study is a multi-center cohort study aiming to find the correlation between PFO closure and migraine attacks.


Eligibility criteria: Inclusion Criteria:

1. Age 18-65 ；
2. Diagnosed migraine by ICHD-3
3. History of migraine longer than 1 year, and symptoms severely disturbing daily life.
4. TCD/TTE/TEE diagnosed patent foramen ovale with right to left shunt
5. Willing to participant and agree to follow-ups
6. Received at least three different types of migraine preventive drugs, the responder rate of previous therapy did not receive 50%.

Exclusion Criteria:

1. Migraine caused by other reason
2. Had TIA/stroke history
3. With contraindication or hypersensitive to anti-platelet or anticoagulation drugs.
4. With contraindication to PFO occlusion

Primary outcomes:
measure: Responder rate
timeFrame: From baseline period to 12-month treatment period
Secondary outcomes:
measure: Migraine days change per month
timeFrame: From baseline period to 12-month treatment period
measure: Number of migraine attacks change per month
timeFrame: From baseline period to 12-month treatment period
measure: Percentage of complete migraine cessation
timeFrame: From baseline period to 12-month treatment period
Other outcomes:
Locations:
city: Beijing
country: China
facility: Fuwai Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT04234737: Efficacy of Hypnotherapy in Children With Dental Anxiety
Official title: Efficacy of Hypnotherapy in Children Aged 8-12 Years Old With Dental Anxiety: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Anxiety
Keywords: dental anxiety
hypnotherapy
pediatric dentistry
Lead sponsor: Ataturk University
Sponsor class: OTHER
First posted: 2020-01-21
Enrollment: 60
Sex: ALL
Minimum age (years): 8
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Dental anxiety is a common problem among the children. The aim of this study is to evaluate the efficacy of hypnotherapy in children with dental anxiety. The participants will be randomized in a 1:1 ratio to hypnotherapy or control group. The outcome measures will be Modified Children Dental Anxiety Scale-faces version(MCDAS(f)) and Visual Analogue Scale(VAS).


Eligibility criteria: Inclusion Criteria:

* initial MCDAS(f) total score \> 19
* ICDAS II (international caries detection and assessment score)= 5 for at least one tooth

Exclusion Criteria:

* presence of dental pain complaint
* non-obtaining the informed consent form

Primary outcomes:
measure: Modified Children Dental Anxiety Scale Faces version MCDAS(f)
timeFrame: maximum 1 week after hypnotherapy.
Secondary outcomes:
measure: Visual Analog Scale (VAS)
timeFrame: during dental treatment
Other outcomes:
Locations:
city: Erzurum
country: Turkey
facility: Ataturk University Faculty of Dentistry Pediatric Dentistry Department
Study officials:
affiliation: assistant professor
name: Fatih Sengul
role: STUDY_DIRECTOR
References:
Clinical trial NCT05716737: Exploring Radiotherapy of Temporomandibular Joint Arthritis
Official title: Exploring Radiotherapy of Temporomandibular Joint Arthritis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Arthritis of Temporomandibular Joint
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2023-02-08
Enrollment: 10
Sex: ALL
Minimum age (years): 50
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: With this pilot study, the acute side effects and potential pain relieve after radiotherapy (RT) of the temporomandibular joint (TMJ) are prospectively recorded.

For this purpose, the symptoms of the jaw joint arthrosis/arthritis are recorded using a symptom-oriented questionnaire and the numeric rating scale for pain assessment.

Furthermore, it is examined whether the irradiation is feasible.


Eligibility criteria: Inclusion Criteria:

* TMJ arthritis
* diagnosed by a surgeon for oral and maxillofacial surgery or a dentist

Exclusion Criteria:

* Previous irradiation in the TMJ area
* Age below 50 years

Primary outcomes:
measure: therapeutic effect
timeFrame: Before, directly after treatment and after 3, 6 9 and 12 months
Secondary outcomes:
measure: Other temporomandibular joint conditions
timeFrame: Before, directly after treatment and after 3, 6 9 and 12 months
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
Study officials:
References:
Clinical trial NCT05039437: Development of Green Mei Products for the Prevention of Metabolic Syndrome
Official title: Development of Green Mei Products for the Prevention of Metabolic Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension
Lead sponsor: Chung Shan Medical University
Sponsor class: OTHER
First posted: 2021-09-09
Enrollment: 50
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to investigate the antihypertensive effects of Mei-Gin formula-4 (MGF-4) and Mei-Gin formula-7.

Detailed description: It's a randomized, and single-blind trial and was designed to evaluate the effects of MGFs (MGF-4 and MGF-4) on blood pressure. 50 participants with hypertension (systolic blood pressure between 130-179 mmHg or diastolic blood pressure between 85-109 mmHg) who did not accept any hypertension medication were randomized allocated to either MGF-4 or MGF-7 group. Participants were instructed to take 4 capsules of MGF-4 or MGF-7 daily throughout the duration of the 8 weeks intervention study. After treatment, the change of the blood pressure and relative mechanism were analyzed.

Eligibility criteria: Inclusion Criteria:

* The age of the subject is 20 to 70 years old.
* The subject is a patient with hypertension (SBP is between 130-179 mmHg, DBP is between 85-109mmHg, one of the two can be diagnosed), and there are no serious illnesses requiring hospitalization during the study period treatment.
* No hypertension medication.
* The subject can understand the test process described in the consent form and the possible potential risks and benefits, and able to sign the consent form.
* The subjects shall observe diet control during the trial period.

Exclusion Criteria:

* Subjects diagnosed with cancer and still under active treatment.
* Subjects diagnosed with heart disease and still under active treatment.
* Other drugs are used, whose pharmacological effects may affect blood pressure or may aggravate the effects of drugs.
* Subjects who have systemic infection and need systemic antibiotics.

Primary outcomes:
measure: Change the blood pressure after intervention
timeFrame: Week 0, 4 and 8
Secondary outcomes:
measure: Change from baseline serum MDA and TEAC at Week 8
timeFrame: Week 0 and 8
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Chung Shan Medical University
state: South
Study officials:
affiliation: Chung Shan Medical University
name: Han-Hui Chang, MS student
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06161337: ChronoMet: Metabolic and Inflammatory Effects of Eating Timing and Quantity
Official title: ChronoMet: Metabolic and Inflammatory Effects of Eating Timing and Quantity
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Healthy Volunteers
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2023-12-07
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This is an observational study to address the important knowledge gap of the metabolic and inflammatory impact of acute overeating and whether timing of acute overeating may modify these effects. The hypothesis is that acute overconsumption of calories will promote inflammation and metabolic dysfunction, with the most detrimental effects observed with evening caloric overconsumption. The expectation is that this study to provide critical insights into the biological consequences of overeating, which will direct novel approaches combating overeating and its detrimental health effects.


Eligibility criteria: Inclusion Criteria:

* ages of 18-65 years old
* not pregnant
* no comorbid conditions
* normal BMI (18.5 - 24.9 kg/m2)
* Weight ≥120 lbs self-reported weight

Exclusion Criteria:

* N/A

Primary outcomes:
measure: Inflammatory markers quantification
timeFrame: 8 months
measure: quantitative metabolomics on serum samples
timeFrame: 8 months
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Lisa Chow, MD,MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02972437: Detection of Group A Streptococcus (GAS) in Oral Cavity
Official title: Detection of Group A Streptococcus (GAS) in Oral Cavity Using Molecular Techniques
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Tonsillitis
Keywords: GAS in oral cavity
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2016-11-23
Enrollment: 100
Sex: ALL
Minimum age (years): 3
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: children 3-16 years old with evidence of tonsilitis

Brief summary: The investigators intend to screen children who are suspected of having GAS tonsillitis. From each child we will take a throat culture and saliva sample to screen for molecular evidence of GAS.


Eligibility criteria: Inclusion Criteria:

* clinical evidence of GAS tonsillitis
* healthy, no chronic illness
* not a GAS carrier

Exclusion Criteria:

* GAS carrier
* Active background disease

Primary outcomes:
measure: molecular detection of GAS compared to throat culture detection
timeFrame: 3 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01897337: The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting
Official title: The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Postoperative Nausea and Vomiting
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2013-07-11
Enrollment: 125
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: PONV (Postoperative nausea and vomiting) is one of most common complications after general anesthesia. Female sex, history of PONV, motion sickness, nonsmoker status, use of volatile agents, duration of anesthesia, opioid administration and laparoscopic surgery are known as risk factors for developing PONV. In consequence, patients undergoing laparoscopic gynecologic surgery are at high risk for developing PONV. Most of these patients use fentanyl based IV-PCA. And it also causes PONV.

So, we should prevent PONV in these patients by using multimodal or combination therapy.

Aprepitant is a NK1 receptor antagonist.And it is used to prevent chemotherapy induced nausea and vomiting. Many studies using aprepitant to prevent PONV are in progress.

In this study, we investigate the effect of combining aprepitant with ondansetron in high-risk patients for PONV.


Eligibility criteria: Inclusion Criteria:

* Patient undergoing laparoscopic gynecologic surgery.
* Patient who takes fentanyl based IV PCA
* ASA class I-II

Exclusion Criteria:

* allergy to aprepitant
* take another antiemetics before surgery
* decreased liver function
* psychological disease
* who cannot speak Korean
* take medicines that interacts with emend who do not agree to the study

Primary outcomes:
measure: incidence and severity of postoperative nausea and vomiting
timeFrame: upto 2 days after surgery
Secondary outcomes:
measure: adverse event
timeFrame: upto 2 days after surgery
measure: pain
timeFrame: upto 2 days after surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Gangnam severance hospital
Study officials:
affiliation: Yonsei University
name: Yon Hee Shim
role: STUDY_DIRECTOR
References:
citation: Ham SY, Shim YH, Kim EH, Son MJ, Park WS, Lee JS. Aprepitant for antiemesis after laparoscopic gynaecological surgery: A randomised controlled trial. Eur J Anaesthesiol. 2016 Feb;33(2):90-5. doi: 10.1097/EJA.0000000000000242.
Clinical trial NCT02934737: Role of markErs in the progreSsion of dIabeteS in Obese paTIeNts
Official title: Role of Some Markers in the Progression of Diabetes in Obese Patients: a 8-year Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obese Patients
Keywords: Obesity
Diabetes Mellitus
Lead sponsor: University of Pavia
Sponsor class: OTHER
First posted: 2016-10-17
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Output patients with obesity

Brief summary: Obese patients will be enrolled from 2006 to 2014. The progression of diabetes mellitus will be observed (if any). Anthropometric and biochemical parameters will be evaluated.


Eligibility criteria: Inclusion Criteria:

* Obesity (body mass index \>/= 30 Kg/m2
* Normal blood glucose (glycemia \< 100 mg/dl)

Exclusion Criteria:

* No exclusion criteria

Primary outcomes:
measure: Progression of diabetes
timeFrame: 8 years
measure: Anthropometric parameters
timeFrame: 8 years
measure: Anthropometric parameters
timeFrame: 8 years
measure: Markers of progression of diabetes
timeFrame: 8 years
measure: Markers of progression of diabetes
timeFrame: 8 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Pavia
name: Giuseppe Derosa, MD, PhD, FESC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02683837: Pupillometry Guided Remifentanil Administration In Pediatric Anesthesia
Official title: A Prospective Randomized Study Evaluating Pupillometry Guided Remifentanil Administration in Pediatric Anesthesia
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Anesthesia
Pain
Child
Keywords: Intraoperative Neurophysiological Monitoring
Reflex, Pupillary
remifentanil
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
First posted: 2016-02-17
Enrollment: 0
Sex: ALL
Minimum age (years): 2
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this prospective randomized study is to evaluate the impact of peroperative pupillometry monitoring on per and post-operative opioid consumption in pediatric anesthesia. All patients are anesthetized with sevoflurane and remifentanil. In the intervention group, peroperative remifentanil infusion rate is guided by pupillometry. In the other group, remifentanil infusion rate is guided according to hemodynamic data.


Eligibility criteria: Inclusion Criteria:

* Children scheduled for a surgery lasting more than 90 minutes.

Exclusion Criteria:

* Contraindication to sevoflurane, to remifentanil or to morphine.
* Peripheral or central nerve block during and after surgery.
* Ophthalmological disease.
* Peroperative position with no acess to the head.
* Chronic use of medication interfering with pupillary diameter.
* Ambulatory surgery

Primary outcomes:
measure: peroperative remifentanil consumption
timeFrame: duration of surgery
Secondary outcomes:
measure: Morphine consumption
timeFrame: during the 24 hour post operative period
measure: Incidence of morphine side effects
timeFrame: during the 24 hour post operative period
measure: Pain scoring (verbal numerical scale)
timeFrame: during the 24 hour post operative period
measure: Pain scoring (questionnaire)
timeFrame: one month post-operatively
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: Geneva Children's Hospital
Study officials:
affiliation: University of Geneva
name: Walid Habre, MD, PhD
role: STUDY_DIRECTOR
References: